MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Inflammatory Bowel Disease
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

6,452 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
6,452 works in the cohort · of 4,299,418page 106 of 130

Labels cover 21 of 6,452 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 6,452 of 6,452 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
P0588 Efficacy and health-related quality of life associated with second-line vedolizumab after one prior first-line anti-tumour necrosis factor treatment in patients with active ulcerative colitis: A meta-analysis of the GEMINI-1 and VISIBLE-1 trials
Raja Atreya, Julien Kirchgesner, Z Cheah, Patricia Biedermann, L Bakker, Morten Meyer +1 more
2025· article· en· Journal of Crohn s and Colitis· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
PWE-076 Dendritic Cell Characteristics in Pouchitis
J. Landy, Hafid O. Al‐Hassi, Elizabeth R. Mann, S. Peake, Paul J. Ciclitira, J Nicholls +3 more
2013· article· en· Gut· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations
affgemma · no categorygpt · no categorymodels agree
P635 Incidence, prevalence, disease phenotype and maximal therapeutic step in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem County cohort
Péter L. Lakatos, Lóránt Gönczi, Petra A. Golovics, Tünde Pandúr, G Dávid, Zsuzsanna Erdélyi +1 more
2022· article· en· Journal of Crohn s and Colitis· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations
affaboutunlabeled
A168 UTILITY OF FOLLOW-UP PANCOLONIC DYE SPRAY CHROMOENDOSCOPY FOR THE DETECTION AND TREATMENT OF DYSPLASTIC LESIONS IDENTIFIED DURING HIGH-DEFINITION WHITE-LIGHT ENDOSCOPY IN PATIENTS WITH COLONIC INFLAMMATORY BOWEL DISEASE
Claudia Dziegielewski, Samir Gupta, Jeffrey D. McCurdy, Richmond Sy, Nav Saloojee, Sanjay K. Murthy
2022· article· en· Journal of the Canadian Association of Gastroenterology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About